AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 32 min read$CTNM

Stengone Carmine N. sold $40K of CTNM

Stengone Carmine N. (CEO and President) sold 2,500 shares of Contineum Therapeutics, Inc. (CTNM) at $16.01 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Stengone Carmine N.
Published Aug 3, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CTNM
Neutral
high confidence
Mentioned
$CTNM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTNMNeutralLow
01

Why it matters

The newest disclosed fact is the CEO’s open-market sale of 2,500 shares at $16.0116 under a pre-arranged 10b5-1 plan.

02

Market read

Primarily a routine insider-sale datapoint; limited standalone trading signal due to 10b5-1 pre-arrangement.

03

What to watch

Traders may want to compare this sale size and frequency to prior Form 4 activity and the company’s recent news flow, which is not provided here.

Relevance 2/10Novelty 3/10Timing: today’s SEC Form 4 filing (2026-08-03)

Background

The article is an SEC Form 4 insider transaction disclosure for Contineum Therapeutics, Inc. (CTNM).

Company-level read

Ticker impact

$CTNMNeutralHigh confidence
Context

Contineum Therapeutics CEO and President Stengone Carmine N. sold 2,500 shares on 2026-08-03 at $16.0116, per Form 4.

Expected impact

Low near-term impact; any reaction is likely muted unless traders suspect plan timing or unusual size versus prior activity.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but it specifies a pre-arranged 10b5-1 plan, reducing interpretive weight for directional forecasting.

Market effects

Sector

No clear sector read-through from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can still coincide with internal liquidity needs or diversification, so it may not reflect bearish fundamentals.

Key entities

  • issuer
    Contineum Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Stengone Carmine N.

    CEO and President who executed the reported sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CTNM insider trading history →

Related articles

OCT 12
$CTNMHigh

Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results

Contineum Therapeutics (CTNM) shares rose 27% premarket after Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for a pulmonary fibrosis treatment targeting the same pathway as CTNM's lead drug, PIPE-791. BMY's trial met its primary endpoint, showing improved lung function. CTNM's stock was indicated at $16.99, up from $13.38. The results may impact CTNM's valuation, though its drug remains in Phase 2.

finance.yahoo.com2 min
OCT 12
MedAI 8/10

Why is Contineum Therapeutics stock surging today?

Contineum Therapeutics stock surged 21.1% after Bristol Myers Squibb's Phase 3 trial for admilparant in pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791, an LPA1 antagonist, benefits from this validation. Analysts have Buy ratings with targets ranging from $20 to $24. The move is driven by company-specific news, not broader market trends.

investing.com2 min
OCT 12
$CTNMHighAI 8/10

Contineum Therapeutics stock surges on Bristol Myers trial win

Contineum Therapeutics (CTNM) shares rose 27% in pre-market trading after Bristol Myers Squibb's Phase 3 trial for admilparant in idiopathic pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791 targets the same biological pathway. CTNM was indicated at $16.99, up from $13.38. Stifel previously noted the trial's importance for Contineum's valuation.

uk.investing.com1 min
SEP 25
$CTNMMedAI 8/10

J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?

Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.

insidermonkey.com4 min